The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessAbstract
The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: 1) the decision to treat high-risk individuals with a glucagon-like peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalization for heart failure (hHF), cardiovascular death, or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualized HbA1c target; 2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and 3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE, and CVD death, as well as in patients with type 2 diabetes with CKD (estimated glomerular filtration rate 30 to ≤60 mL min–1 [1.73 m]–2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE, and cardiovascular death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During the time between initiation and completion of the FIDELIO-DKD and FIGARO-DKD trials, numerous rigorous clinical trials demonstrated large kidney and cardiovascular bene fi ts of SGLT2i (Section 1.3 above), and SGLT2i became an established fi rst-line treatment for T2D with CKD.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [143]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prioritization of SGLT2i therapy in high-risk patients such as those with CKD is consistent with the recommendations from other professional societies including the American College of Cardiology (ACC), 142 the joint statement by the ADA and the European Association of the Study of Diabetes (EASD), 143 and the joint guideline by the European Society of Cardiology (ESC) and EASD.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1×
“Somemeta-analyses (5,13,14) suggest the presence of heterogeneity in estimates forMACE andCVdeathwithGLP-1 receptor agonists, although this ismostly due to the results of a single trial with lixisenatide.”
ResultDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Self-citationRosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Cited by
Sorted by citations
Items 201–300 of 1,000
Mody, R., Yu, M. B., Nepal, B., Кониг, М., & Grabner, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14195 · Cited by 37
A Metabolic Pattern in Healthy Subjects Given a Single Dose of Metformin: A Metabolomics Approach
Dahabiyeh, L. A., Mujammami, M. H., Arafat, T., Benabdelkamel, H., Alfadda, A. A., & Rahman, A. M. A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.705932 · Cited by 39
Li, C. X., Liu, L. Y., Zhang, C. X., Geng, X. H., Gu, S. M., Wang, Y. Q., Liu, H., Xie, Q., & Liang, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1238399 · Cited by 38
Marzullo, P., Daffara, T., Mele, C., Zavattaro, M., Ferrero, A., Caputo, M., Prodam, F., & Aimaretti, G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01799-2 · Cited by 34
Venkatasubramaniam, A., Mateen, B. A., Shields, B. M., Hattersley, A. T., Jones, A. G., Vollmer, S. J., & Dennis, J. (2023) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-023-02207-2 · Cited by 40
Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin
Cowart, K. (2020) · Clinical Diabetes · doi:10.2337/cd19-0061 · Cited by 38
Cefalu, W. T., Andersen, D. K., Arreaza-Rubín, G., Pin, C. L., Sato, S. M., Verchere, C. B., Woo, M., & Rosenblum, N. D. (2021) · Diabetes Care · doi:10.2337/dci21-0051 · Cited by 36
Zhou, T., Liu, P., Dhruva, S. S., Shah, N. D., Ramachandran, R., Berg, K. M., & Ross, J. S. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.7457 · Cited by 35
Lu, J., Wang, C., Cai, J., Shen, Y., Chen, L., Zhang, L., Lu, W., Zhu, W., Hu, G., Xia, T., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab532 · Cited by 33
Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder
Nakhal, M. M., Aburuz, S., Sadek, B. S., & Akour, A. A. (2022) · Molecules · doi:10.3390/molecules27217174 · Cited by 33
King, A., & Miller, E. M. (2022) · Clinical Diabetes · doi:10.2337/cd22-0027 · Cited by 33
Impact of Intensive Glycemic Treatment on Diabetes Complications—A Systematic Review
Poonoosamy, J., Lopes, P., Huret, P., Dardari, R., Penfornis, A., Thomas, C., & Dardari, D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071791 · Cited by 43
Prevalence of diabetes, epidemiological characteristics and vascular complications
Russo, M. P., Ratti, M. F. G., Burgos, M. A., Molaro, A. A., & Bonella, M. B. (2023) · Archivos de cardiolog�a de M�xico (English ed Internet) · doi:10.24875/acme.m23000372 · Cited by 34
The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis
Stachteas, P., Karakasis, P., Patoulias, D., Clemenza, F., Fragakis, N., & Rizzo, M. (2023) · Annals of Medicine · doi:10.1080/07853890.2024.2304667 · Cited by 35
The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure
Stachteas, P., Nasoufidou, A., Patoulias, D., Karakasis, P., Karagiannidis, E., Mourtzos, M.-A., Samaras, A., Apostolidou, X., & Fragakis, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063122 · Cited by 33
Wright, E. E., & Aroda, V. R. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798127 · Cited by 38
Lan, N. S. R., Yeap, B. B., Fegan, P. G., Green, G., Rankin, J. M., & Dwivedi, G. (2020) · International journal of cardiac imaging · doi:10.1007/s10554-020-02034-w · Cited by 32
Espeland, M. A., Pratley, R. E., Rosenstock, J., Kadowaki, T., Seino, Y., Zinman, B., Marx, N., McGuire, D. K., Andersen, K. R., Mattheus, M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14254 · Cited by 33
Akter, S., Akhter, H., Chaudhury, H. S., Rahman, M. H., Gorski, A., Hasan, M. N., Shin, Y., Rahman, M. A., Nguyen, M. N., Choi, T. G., et al. (2022) · BioFactors · doi:10.1002/biof.1886 · Cited by 34
Liu, Y., Li, J., Yan, Z., Liu, D., Ma, J., & Tong, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.657889 · Cited by 34
Gong, L., Wang, C., Ning, G., Wang, W., Chen, G., Wan, Q., Qin, G., Yan, L., Wang, G., Qin, Y., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14502 · Cited by 34
Singh, A. K., & Singh, R. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i6.329 · Cited by 32
Fu, E. L., D’Andrea, E., Wexler, D. J., Patorno, E., & Paik, J. M. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000115 · Cited by 35
Self-citationPatti, A. M., Giglio, R. V., Allotta, A., Bruno, A., Bella, T. D., Stoian, A. P., Ciaccio, M., & Rizzo, M. (2023) · Biomedicines · doi:10.3390/biomedicines11051362 · Cited by 34
Skriver, C., Friis, S., Knudsen, L. B., Catarig, A., Clark, A. J., Dehlendorff, C., & Mørch, L. S. (2023) · Diabetologia · doi:10.1007/s00125-023-05972-x · Cited by 36
Drug Therapies Affecting Renal Function: An Overview
Alhassani, R. Y., Bagadood, R. M., Balubaid, R. N., Barno, H. I., Alahmadi, M. O., & Ayoub, N. (2021) · Cureus · doi:10.7759/cureus.19924 · Cited by 40
Improving Stroke Risk Factor Management Focusing on Health Disparities and Knowledge Gaps
Sur, N. B., Kozberg, M. G., Desvigne-Nickens, P. M., Silversides, C. K., Bushnell, C., Goldstein, L. B., Saver, J. L., Broderick, J. P., Gökçal, E., Merino, J. G., et al. (2023) · Stroke · doi:10.1161/strokeaha.122.040449 · Cited by 36
Castellana, M., Procino, F., Sardone, R., Trimboli, P., & Giannelli, G. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01067-8 · Cited by 31
Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management
Shroff, H., & VanWagner, L. B. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00530-0 · Cited by 33
Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls
Andersen, A., Bagger, J. I., BALDASSARRE, M. P. A., Christensen, M., ABELIN, K. U., Faber, J. O., Pedersen‐Bjergaard, U., Holst, J. J., Lindhardt, T. B., Gislason, G., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0232 · Cited by 32
Meligi, N. M., Dyab, A. K. F., & Paunov, V. N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071048 · Cited by 32
Block, C. E. M. D., Dirinck, E. L., Verhaegen, A. A., & Gaal, L. F. V. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 33
Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease
Karalliedde, J. J., Winocour, P. H., Chowdhury, T. A., De, P., Frankel, A., Montero, R., Pokrajac, A., Banerjee, D., Dasgupta, I., Fogarty, D. G., et al. (2022) · Diabetic Medicine · doi:10.1111/dme.14769 · Cited by 33
Shimose, S., Hiraoka, A., Gardini, A. C., Tsutsumi, T., Nakano, D., Iwamoto, H., Tada, F., Rimini, M., Tanaka, M., Torimura, T., et al. (2022) · Hepatology Research · doi:10.1111/hepr.13843 · Cited by 31
Wang, Y., He, W., Wei, W., Mei, X., Yang, M., & Wang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.622737 · Cited by 30
First-line treatment for type 2 diabetes: is it too early to abandon metformin?
Zaccardi, F., Khunti, K., Marx, N., & Davies, M. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32523-x · Cited by 31
Self-citationBarrea, L., Vetrani, C., Caprio, M., Ghoch, M. E., Frías-Toral, E., Mehta, R. J., Méndez, V., Moriconi, E., Paschou, S. Α., Pazderska, A., et al. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1980766 · Cited by 30
Zhang, H., Wang, P., Shi, D., Yao, X., Li, Y., Liu, X., Sun, Y., Ding, J., Wang, S., Wang, G., et al. (2022) · European Radiology · doi:10.1007/s00330-021-08415-6 · Cited by 30
Chow, E., Yang, A., Chung, C. H. L., & Chan, J. C. N. (2022) · Pharmaceuticals · doi:10.3390/ph15040442 · Cited by 30
Protection by metformin against severe Covid-19: An in-depth mechanistic analysis
Wiernsperger, N. F., Al‐Salameh, A., Cariou, B., & Lalau, J. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101359 · Cited by 31
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Złotek, M., Kurowska, A., Herbet, M., & Piątkowska‐Chmiel, I. (2023) · Biomedicines · doi:10.3390/biomedicines11113035 · Cited by 30
Yaseen, A., & Lahiri, S. W. (2023) · Clinical Diabetes · doi:10.2337/cd22-0100 · Cited by 37
Silvestris, N., Franchina, T., Gallo, M., Argentiero, A., Avogaro, A., Cirino, G., Colao, A. A. L., Danesi, R., Cianni, G. D., D’Oronzo, S., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102062 · Cited by 32
Liang, L., Su, X., Guan, Y., Wu, B., Zhang, X., & Nian, X. (2024) · iScience · doi:10.1016/j.isci.2024.109784 · Cited by 33
Tubular effects of sodium–glucose cotransporter 2 inhibitors: intended and unintended consequences
Rieg, J. A. D., Xue, J., & Rieg, T. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000632 · Cited by 32
Chambergo‐Michilot, D., Tauma‐Arrué, A., & Loli-Guevara, S. (2020) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2020.100690 · Cited by 30
Mehta, R., Goldenberg, R., Katselnik, D., & Kuritzky, L. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1925148 · Cited by 29
Fu, E. L., Clase, C. M., Janse, R. J., Lindholm, B., Dekker, F. W., Jardine, M., & Carrero, J. J. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.01.042 · Cited by 29
Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists
Madsbad, S., & Holst, J. J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac112 · Cited by 37
Ramos, M., Cummings, M. H., Ustyugova, A., Raza, S. I., de Silva, S. U., & Lamotte, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00883-1 · Cited by 29
Ferrannini, G., Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Díaz, R., Dyal, L., Lakshmanan, M. C., Mellbin, L., Probstfield, J. L., Riddle, M. C., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa777 · Cited by 28
Thomsen, R. W., Knudsen, J. S., Kahlert, J. A., Baggesen, L. M., Lajer, M., Holmgaard, P., Vedin, O., Ustyugova, A., & Sørensen, H. T. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019356 · Cited by 28
Dapagliflozin for the treatment of type 2 diabetes mellitus – an update
Nicholson, M., Asswad, R. G., & Wilding, J. P. H. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1953471 · Cited by 31
Yanai, H., Hakoshima, M., Adachi, H., & Katsuyama, H. (2022) · Cardiology Research · doi:10.14740/cr1441 · Cited by 28
Sun, C., Shenk, Z., Renda, S., Maruthur, N. M., Zheng, S., Perrin, N., Levin, S., & Han, H. (2023) · JMIR Diabetes · doi:10.2196/44283 · Cited by 31
Berg, T., Aehling, N., Bruns, T., Welker, M., Weismüller, T. J., Trebicka, J., Tacke, F., Strnad, P., Sterneck, M. R., Settmacher, U., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2255-7246 · Cited by 30
Type 2 diabetes mellitus management in patients with chronic kidney disease: an update
Kleinaki, Z., Kapnisi, S., Theodorelou‐Charitou, S., Nikas, I. P., & Paschou, S. Α. (2020) · HORMONES · doi:10.1007/s42000-020-00212-y · Cited by 27
Green, J. B., Everett, B. M., Ghosh, A., Younes, N., Krause-Steinrauf, H. J., Barzilay, J. I., Desouza, C. V., Inzucchi, S. E., Pokharel, Y., Schade, D. S., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.066604 · Cited by 28
Güdemann, L. M., Young, K. G., Thomas, N. J., Hopkins, R., Challen, R., Jones, A. G., Hattersley, A. T., Pearson, E. R., Shields, B. M., Bowden, J., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06190-9 · Cited by 27
Lim, C.-E., Pasternak, B., Eliasson, B., & Ueda, P. (2025) · Diabetologia · doi:10.1007/s00125-025-06439-x · Cited by 27
Tanaka, A., Shimabukuro, M., Machii, N., Teragawa, H., Okada, Y., Shima, K. R., Takamura, T., Taguchi, I., Hisauchi, I., Toyoda, S., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13289 · Cited by 26
Zaccardi, F., Jacquot, E., Cortese, V., Tyrer, F., Seidu, S., Davies, M. J., & Khunti, K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14169 · Cited by 30
Self-citationVolke, V., Katus, U., Johannson, A., Toompere, K., Heinla, K., Rünkorg, K., & Uusküla, A. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01158-5 · Cited by 30
Multi-organ denervation: a novel approach to combat cardiometabolic disease
Kiuchi, M. G., Carnagarin, R., Matthews, V. B., & Schlaich, M. P. (2023) · Hypertension Research · doi:10.1038/s41440-023-01287-x · Cited by 27
The Interplay of Autophagy and Oxidative Stress in the Kidney: What Do We Know?
Guo, H., & Bechtel‐Walz, W. (2023) · The Nephron journals/Nephron journals · doi:10.1159/000531290 · Cited by 31
Candido, R., Gaiotti, S., Giudici, F., Toffoli, B., Luca, F. D., Velardi, V., Petrucco, A., Gottardi, C., Manca, E., Buda, I., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186052 · Cited by 29
Wolffenbuttel, B. H. R., Brugts, M. P., Catarig, A.-M., Clark, A., Kok, M., Lieverse, A. G., & van Soest, J. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02385-x · Cited by 26
Zheng, J., Lu, J., Qi, J., Yang, Q., Zhao, H., Liu, H., Chen, Z., Huang, L., Ye, Y., Xu, M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101688 · Cited by 29
Huynh, Q. T., Pham, N. M., Pham, D. T., Hoang, M. T., Dam, L. T. P., Ho, H. T., Phan, V. A., Can, L. T., Ngo, T. T. M., Dang, D. Q., et al. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s258678 · Cited by 28
Mosenzon, O., Bain, S. C., Heerspink, H. J. L., Idorn, T., Mann, J. F. E., Persson, F., Pratley, R. E., Rasmussen, S., Rossing, P. R., von Scholten, B. J., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14126 · Cited by 26
Self-citationMorieri, M. L., Avogaro, A., & Fadini, G. P. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s216054 · Cited by 29
Hallström, S., Wijkman, M. O., Ludvigsson, J., Ekman, P., Pfeffer, M. A., Wedel, H., Rosengren, A., & Lind, M. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100469 · Cited by 30
Lim, J., Hwang, I., Choi, H., Yoon, Y. E., & Cho, G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269414 · Cited by 24
Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights
Baek, H.-S., Jeong, C., Yang, Y., Lee, J., Lee, J., Lee, S., Cho, J., Sohn, T. S., Son, H.-S., Yoon, K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0036 · Cited by 30
Consoli, A., Czupryniak, L., Duarte, R., Jermendy, G., Kautzky‐Willer, A., Mathieu, C., Melo, M., Mosenzon, O., Nobels, F. R. E., Παπάνας, Ν., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14102 · Cited by 26
Self-citationBonora, B. M., Rigato, M., Frison, V., D'Ambrosio, M., Tadiotto, F., Lapolla, A., Simioni, N., Paccagnella, A., Avogaro, A., & Fadini, G. P. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108686 · Cited by 26
Sun, J., Liu, H., Zhang, Y., Fang, Z.-Y., & Lv, P. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105342 · Cited by 25
Eroglu, T. E., Coronel, R., Zuurbier, C. J., Blom, M. T., de Boer, A., & Souverein, P. C. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac043 · Cited by 25
Sciacca, L., Bianchi, C., Burlina, S., Formoso, G., Manicardi, E., Sculli, M. A., & Resi, V. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02137-5 · Cited by 28
Pilmark, N. S., Lyngbæk, M. P. P., Oberholzer, L., Elkjær, I., Petersen-Bønding, C., Kofoed, K., Siebenmann, C., Kellenberger, K., van Hall, G., Abildgaard, J., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05282-6 · Cited by 26
Kitazawa, M., Katagiri, T., Suzuki, H., Matsunaga, S., Yamada, M. H., Ikarashi, T., Yamamoto, M., Furukawa, K., Iwanaga, M., Hatta, M., et al. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14288 · Cited by 28
Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials
Ludwig, L., Darmon, P., & Guerci, B. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01034-3 · Cited by 25
Men, P., Liu, T., & Zhai, S. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s266901 · Cited by 24
Banach, M., Gaiță, D. I., Haluzı́k, M., Janež, A., Kamenov, Z. A., Kempler, P., Lalic, N. M., Linhart, A., Mikhailidis, D. P., Nocoń, A., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108535 · Cited by 24
Ritsinger, V., Lagerqvist, B., Lundman, P., Hagström, E., & Norhammar, A. (2020) · Diabetes and Vascular Disease Research · doi:10.1177/1479164120973676 · Cited by 23
Giusti, L., Tesi, M., Ciregia, F., Marselli, L., Zallocco, L., Suleiman, M., Luca, C. D., Guerra, S. D., Zuccarini, M., Trerotola, M., et al. (2022) · Cells · doi:10.3390/cells11152465 · Cited by 22
Oikonomaki, D., Dounousi, E. C., Duni, Α., Roumeliotis, S. K., & Liakopoulos, V. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108604 · Cited by 25
Pratley, R. E., Catarig, A., Lingvay, I., Viljoen, A., Paine, A., Lawson, J., Chubb, B., Gorst‐Rasmussen, A., & Miresashvili, N. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14497 · Cited by 24
Goldenberg, R. M., Ahooja, V., Clemens, K. K., Gilbert, J. D., Poddar, M., & Verma, S. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.005 · Cited by 23
The risk of cardiovascular complications with current obesity drugs
Chao, A. M., Wadden, T. A., Berkowitz, R. I., Quigley, K., & Silvestry, F. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1806234 · Cited by 23
Davies, M. J., Bianchi, C., & Prato, S. D. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154242 · Cited by 24
Self-citationMorieri, M. L., Consoli, A., Sesti, G., Purrello, F., Avogaro, A., Fadini, G. P., & for the DARWIN‐FUP network (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3353 · Cited by 22
Ertuğlu, L. A., Porrini, E., Hornum, M., Demiray, A., Afşar, B., Ortíz, A., Covic, A. C., Rossing, P. R., & Kanbay, M. (2021) · Transplant International · doi:10.1111/tri.13883 · Cited by 25
Self-citationWang, R., & Liu, H. (2021) · Hormone and Metabolic Research · doi:10.1055/a-1475-4444 · Cited by 23
Genetics of Type 2 Diabetes: Opportunities for Precision Medicine
Kim, D. S., Gloyn, A. L., & Knowles, J. W. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.346 · Cited by 25
El‐Boshy, M., Alsaegh, A., Qasem, A. H., Sindi, R. A., Abdelghany, A. H., Gadalla, H., Reda, D., Azzeh, F. S., Idris, S., Ahmad, J., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.08.010 · Cited by 23
Branco, A., Fatima, R., Liblik, K., Jackson, R., Payne, D. M., & El-Diasty, M. M. (2022) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2022.06.008 · Cited by 23
Shirabe, S., Yamazaki, K., Oishi, M., Arai, K., Yagi, N., Sato, M., Takeuchi, M., Kai, T., & Maegawa, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13922 · Cited by 23
Jung, H., Tittel, S. R., Schloot, N. C., Heitmann, E., Otto, T., Lebrec, J., Pavel, M., & Lanzinger, S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15038 · Cited by 23
The South Asian Health Foundation (UK) guidelines for managing diabetes during Ramadan
Hanif, W., Patel, V., Ali, S., Karamat, A., Saeed, M. A., Hassanein, M. M., Syed, A., Chowdhury, T. A., Farooqi, A., & Khunti, K. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108145 · Cited by 27
Metadata
- Authors
- Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- Second Medical Department, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of Copenhagen (DK)
- Università Cattolica del Sacro Cuore (IT)
- Universitair Ziekenhuis Leuven (BE)
- Duke University (US)
- University of Leicester (GB)
- Corresponding author
- Davies, Melanie J.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-12-19
- Volume
- 43
- Issue
- 2
- Pages
- 487-493
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6971782
- OpenAlex
- W4253996779
- Cited by
- 1,192
- References
- 21
- Citations by year
- 2026: 54 · 2025: 79 · 2024: 128 · 2023: 162 · 2022: 277 · 2021: 279 · 2020: 212
- FWCI
- 155.76
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-07-01)
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- Lirias (submittedVersion)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
- Funders
- American Diabetes Association
- European Association for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- hyperglycemia management, type 2 diabetes, GLP-1 receptor agonists, SGLT2 inhibitors, major adverse cardiovascular events, heart failure hospitalization, heart failure with reduced ejection fraction, chronic kidney disease progression, HbA1c targets, cardiovascular risk stratification
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
